Clinical Trial Update: A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions [Phase 2, Phase 3]

View source ↗

Summary

Completed randomized, double-blind study evaluating paclitaxel-eluting stents for longer coronary lesions in coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS Paclitaxel-Eluting Stent (paclitaxel-eluting stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Artery Disease | Phase 2, Phase 3 | Status: COMPLETED